AR123793A1 - Compuestos de triazolopiridinilo como inhibidores de quinasas - Google Patents
Compuestos de triazolopiridinilo como inhibidores de quinasasInfo
- Publication number
- AR123793A1 AR123793A1 ARP210102843A ARP210102843A AR123793A1 AR 123793 A1 AR123793 A1 AR 123793A1 AR P210102843 A ARP210102843 A AR P210102843A AR P210102843 A ARP210102843 A AR P210102843A AR 123793 A1 AR123793 A1 AR 123793A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- haloalkyl
- deuteroc1
- deuteroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos que tienen la fórmula (1) y enantiómeros y diastereómeros, estereoisómeros, sales farmacéuticamente aceptables de los mismos, son útiles como moduladores de quinasas, incluida la modulación RIPK1. Todas las variables son como se definen en el presente documento. Reivindicación 1: Un compuesto que tiene la fórmula (1), o una sal del mismo, en donde R¹ es H, alquilo C₁₋₃, alcoxilo C₁₋₃, haloalquilo C₁₋₃, haloalcoxilo C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxilo C₁₋₃, halógeno, o ciclopropilo; R² es H, o halo; R³ es H, halo, o alquilo C₁₋₃ o deuteroalquilo C₁₋₃; R⁴ es H o F; R⁵ᵃ y R⁵ᵇ son cada uno independientemente H, deuterio, alquilo C₁₋₃ o haloalquilo C₁₋₃; alternativamente, R⁵ᵃ y R⁵ᵇ se unen para formar ciclopropilo; R⁶ᵃ y R⁶ᵇ son cada uno independientemente H, deuterio, OH, F, alquilo C₁₋₃, o C(O)-4-fluorofenilo; alternativamente, R⁶ᵃ y R⁶ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R⁷ᵃ y R⁷ᵇ son cada uno independientemente H, deuterio, OH, OP(O)(OR)₂, OC(O)NH₂, NH₂, F, alquilo C₁₋₃, alcoxi C₁₋₃, OCD₃, o haloalquilo C₁₋₃; alternativamente, R⁷ᵃ y R⁷ᵇ son =O, o se unen para formar ciclopropilo o oxetanilo; R es H o alquilo C₁₋₃; R⁸ es H, F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, deuteroalquilo C₁₋₃, o deuteroalcoxi C₁₋₃; R⁹ es H o CH₃; el anillo Z es fenilo, un anillo heteroarilo de 6 miembros que tiene 1 - 2 átomos de nitrógeno, ciclohexilo, ciclopentilo, o ciclobutilo; Y es F, Cl, alquilo C₁₋₃, alcoxi C₁₋₃, CN, haloalquilo C₁₋₃, haloalcoxi C₁₋₃, deuteroalquilo C₁₋₃, deuteroalcoxi C₁₋₃, C(O)OCH₃, o C&
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063093463P | 2020-10-19 | 2020-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123793A1 true AR123793A1 (es) | 2023-01-11 |
Family
ID=78536657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102843A AR123793A1 (es) | 2020-10-19 | 2021-10-14 | Compuestos de triazolopiridinilo como inhibidores de quinasas |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11767322B2 (es) |
| EP (2) | EP4364737A3 (es) |
| JP (1) | JP7730897B2 (es) |
| KR (1) | KR20230092960A (es) |
| CN (1) | CN116802181A (es) |
| AR (1) | AR123793A1 (es) |
| AU (1) | AU2021364302A1 (es) |
| CA (1) | CA3196059A1 (es) |
| CL (1) | CL2023001123A1 (es) |
| CO (1) | CO2023004926A2 (es) |
| DK (1) | DK4229056T3 (es) |
| ES (1) | ES2987662T3 (es) |
| FI (1) | FI4229056T3 (es) |
| HR (1) | HRP20240739T1 (es) |
| HU (1) | HUE067776T2 (es) |
| IL (1) | IL302113A (es) |
| LT (1) | LT4229056T (es) |
| MX (1) | MX2023004492A (es) |
| PE (1) | PE20240219A1 (es) |
| PL (1) | PL4229056T3 (es) |
| PT (1) | PT4229056T (es) |
| RS (1) | RS65620B1 (es) |
| SI (1) | SI4229056T1 (es) |
| SM (1) | SMT202400242T1 (es) |
| TW (1) | TW202233614A (es) |
| WO (1) | WO2022086828A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3580220T (lt) * | 2017-02-13 | 2021-12-27 | Bristol-Myers Squibb Company | Aminotriazolopiridinai, kaip kinazės inhibitoriai |
| IL291828A (en) | 2019-10-03 | 2022-06-01 | Bristol Myers Squibb Co | Inazole Carboximides as Kinase Inhibitors |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| AR133938A1 (es) | 2023-09-27 | 2025-11-19 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo unidos a éter como inhibidores de cinasa |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077948A1 (ja) | 2004-02-16 | 2005-08-25 | Daiichi Pharmaceutical Co., Ltd. | 抗真菌作用複素環化合物 |
| EP1765825A1 (en) | 2004-06-25 | 2007-03-28 | Amgen Inc. | Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| WO2009128520A1 (ja) | 2008-04-18 | 2009-10-22 | 塩野義製薬株式会社 | Ｐ１３ｋ阻害活性を有する複素環化合物 |
| WO2010007099A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| CA2750517A1 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| CN105246891A (zh) | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| US10214537B2 (en) | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| JP6763396B2 (ja) | 2015-11-05 | 2020-09-30 | 住友化学株式会社 | 縮合複素環化合物 |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| WO2018139436A1 (ja) | 2017-01-24 | 2018-08-02 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| LT3580220T (lt) * | 2017-02-13 | 2021-12-27 | Bristol-Myers Squibb Company | Aminotriazolopiridinai, kaip kinazės inhibitoriai |
| WO2018237370A1 (en) | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
| AU2018361249B2 (en) * | 2017-10-30 | 2022-08-25 | Bristol-Myers Squibb Company | Aminoimidazopyridazines as kinase inhibitors |
| WO2019147782A1 (en) | 2018-01-26 | 2019-08-01 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| CA3112735A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| MX2021002617A (es) | 2018-09-13 | 2021-05-12 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| US20220177462A1 (en) | 2019-03-22 | 2022-06-09 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| IL291828A (en) | 2019-10-03 | 2022-06-01 | Bristol Myers Squibb Co | Inazole Carboximides as Kinase Inhibitors |
| CN114230565B (zh) | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2021
- 2021-10-14 AR ARP210102843A patent/AR123793A1/es not_active Application Discontinuation
- 2021-10-18 PL PL21805787.5T patent/PL4229056T3/pl unknown
- 2021-10-18 PE PE2023001446A patent/PE20240219A1/es unknown
- 2021-10-18 HU HUE21805787A patent/HUE067776T2/hu unknown
- 2021-10-18 CN CN202180070933.6A patent/CN116802181A/zh active Pending
- 2021-10-18 AU AU2021364302A patent/AU2021364302A1/en not_active Abandoned
- 2021-10-18 IL IL302113A patent/IL302113A/en unknown
- 2021-10-18 KR KR1020237016535A patent/KR20230092960A/ko active Pending
- 2021-10-18 US US17/503,516 patent/US11767322B2/en active Active
- 2021-10-18 WO PCT/US2021/055340 patent/WO2022086828A1/en not_active Ceased
- 2021-10-18 FI FIEP21805787.5T patent/FI4229056T3/fi active
- 2021-10-18 RS RS20240656A patent/RS65620B1/sr unknown
- 2021-10-18 DK DK21805787.5T patent/DK4229056T3/da active
- 2021-10-18 SI SI202130138T patent/SI4229056T1/sl unknown
- 2021-10-18 CA CA3196059A patent/CA3196059A1/en active Pending
- 2021-10-18 PT PT218057875T patent/PT4229056T/pt unknown
- 2021-10-18 TW TW110138596A patent/TW202233614A/zh unknown
- 2021-10-18 HR HRP20240739TT patent/HRP20240739T1/hr unknown
- 2021-10-18 MX MX2023004492A patent/MX2023004492A/es unknown
- 2021-10-18 JP JP2023523570A patent/JP7730897B2/ja active Active
- 2021-10-18 SM SM20240242T patent/SMT202400242T1/it unknown
- 2021-10-18 EP EP24159615.4A patent/EP4364737A3/en active Pending
- 2021-10-18 ES ES21805787T patent/ES2987662T3/es active Active
- 2021-10-18 EP EP21805787.5A patent/EP4229056B1/en active Active
- 2021-10-18 LT LTEPPCT/US2021/055340T patent/LT4229056T/lt unknown
-
2023
- 2023-04-18 CL CL2023001123A patent/CL2023001123A1/es unknown
- 2023-04-19 CO CONC2023/0004926A patent/CO2023004926A2/es unknown
- 2023-07-06 US US18/347,703 patent/US12110290B2/en active Active
-
2024
- 2024-08-28 US US18/817,352 patent/US20240425505A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123793A1 (es) | Compuestos de triazolopiridinilo como inhibidores de quinasas | |
| AR119821A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
| AR130165A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con ellos | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| PE20201202A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| AR093403A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| MX2019009555A (es) | Aminotriazolopiridinas como inhibidores de cinasa. | |
| AR091022A1 (es) | Inhibidores del nampt | |
| ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| PE20212070A1 (es) | Moduladores de trex1 | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR095530A1 (es) | Moduladores de p2x7 | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR073055A1 (es) | Derivados biciclicos de triazol | |
| AR072192A1 (es) | Derivados de tiazolil-piperidina | |
| AR101964A1 (es) | Compuestos de imidazopiridazina como moduladores de pi3k | |
| AR090103A1 (es) | Derivados ciclicos de diaminopirimidina | |
| AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
| AR111672A1 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |